22245-96-1

Usage

Uses

Used in Neuropharmacological Research:
7-NITRO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE is used as a research compound for studying its effects on neurotransmitter systems and its potential as a drug candidate for the treatment of various neurological disorders.
Used in Anticancer Research:
7-NITRO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE is used as a research compound for investigating its potential anticancer properties. Further research is needed to fully understand its chemical properties and potential applications in the field of medicine and drug development.

InChI:InChI=1/C9H8N2O3/c12-9-8-5-7(11(13)14)2-1-6(8)3-4-10-9/h1-2,5H,3-4H2,(H,10,12)

Upstream product

• 86288-79-1 2,7-Dinitro-3,4-dihydroisocarbostyryl 
• 2257-09-2 Phenethyl isothiocyanate 
• 66491-03-0 7-amino-3,4-dihydroisoquinoline-1(2H)-one 
• 1943-82-4 phenethyl isocyanate 
• 31349-66-3 methyl 2-((phenethylcarbamoyl)oxy)benzoate 
• 83-33-0 inden-1-one 
• 24954-67-4 2-(p-nitrophenyl)ethylamine 
• 555-21-5 4-Nitrophenylacetonitrile 
• 64-04-0 phenethylamine 
• 6970-83-8 ethyl-N-(2-phenethyl)carbamate 
• 6552-60-9 3,4-dihydro-2H-isoquinoline-1-thione 
• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 1196-38-9 3,4-dihydroisoquinolin-1(2H)-one 

Downstream Products

• 62541-63-3 5-Iodo-2-(2-pyrrol-1-ylethyl)benzoic acid 
• 62541-67-7 2-(2-Pyrrol-1-ylethyl)-5-nitro benzoic acid 
• 22246-05-5 7-hydroxy-3,4-dihydro-1-oxo-2(1H)-isoquinoline 
• 1368661-06-6 7-phenyl-3,4-dihydroisoquinolin-1(2H)-one 
• 891782-60-8 7-bromo-3,4-dihydroisoquinolin-1(2 H)-one 
• 1036388-74-5 C₁₉H₂₀N₂O₅ 
• 897374-26-4 7-hydrazino-3,4-dihydro-2H-isoquinolin-1-one 
• 42923-79-5 7-nitro-1,2,3,4-tetrahydroisoquinoline 

Relevant academic research and scientific papers

1,2,4-Triazole-3-Thione Analogues with a 2-Ethylbenzoic Acid at Position 4 as VIM-type Metallo-β-Lactamase Inhibitors

Metallo-β-lactamases (MBLs) are increasingly involved as a major mechanism of resistance to carbapenems in relevant opportunistic Gram-negative pathogens. Unfortunately, clinically efficient MBL inhibitors still represent an unmet medical need. We previou

HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS

The present invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; (I) which are inhibitors of WDR5. The present invention also provides pharmaceutical compositions comprising such compounds, compositions comprising such compounds with an additional therapeutic agent and the therapeutic uses of such compounds.

Cyclic-fused ASK1 inhibitor and application thereof

The invention relates to a cyclic-fused ASK1 inhibitor and application thereof, and particularly to a compound shown in formula (I), a pharmacologically acceptable salt and ester thereof, and a stereisomer thereof. The invention further relates to a preparation method of the compound, a pharmaceutic preparation and a pharmaceutical composition containing the compound. The compound of the inventionis capable of effectively inhibiting phosphorylation of amino acid of ASK1, and inhibiting the activation of the ASK1, thereby can be used for treating and/or preventing ASK1-mediated diseases and related diseases.

PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.

Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors

Inhibitors of Factor VIIa (FVIIa), a serine protease in the clotting cascade, have shown strong antithrombotic efficacy in preclinical thrombosis models with minimal bleeding liabilities. Discovery of potent, orally active FVIIa inhibitors has been largely unsuccessful because known chemotypes have required a highly basic group in the S1 binding pocket for high affinity. A recently reported fragment screening effort resulted in the discovery of a neutral heterocycle, 7-chloro-3,4-dihydroisoquinolin-1(2H)-one, that binds in the S1 pocket of FVIIa and can be incorporated into a phenylglycine FVIIa inhibitor. Optimization of this P1 binding group led to the first series of neutral, permeable FVIIa inhibitors with low nanomolar potency.

A kind of diaryl hydanto?n derivatives, its preparation method, pharmaceutical composition and application

Provided are a compound as represented by formula I, or pharmaceutically acceptable salt, solvate, precursor drug, stereoisomer, tautomer, polymorph or metabolite thereof, pharmaceutical composition containing same, and uses thereof in the preparation of drugs for treating androgen receptor related diseases.

Facile synthesis of 5-To 7-membered benzolactam compounds via strongly facilitated electrophilic aromtic substitution reaction

We employed our system to activate aromatic ring-Tethered carbamate compounds with trifluoromethanesulfonic acid to obtain benzolactams with 5-To 7-membered rings, and examined the substrate scope and limitations of this activation method. In 5-membered ring formation, a halogen group on the aromatic ring did not greatly affect the reaction yield, but other electron-donating groups inhibited the cyclization reaction, and various side-reactions occurred. In 7-membered ring formation, eletron-donating groups on aromatic ring promoted the cyclization reaction, but cyclization of electron-deficient aromatic rings did not proceed well. The 6-membered ring formation reaction showed the greatest substrate generality.

Discovery of novel P1 groups for coagulation factor VIIa inhibition using fragment-based screening

A multidisciplinary, fragment-based screening approach involving protein ensemble docking and biochemical and NMR assays is described. This approach led to the discovery of several structurally diverse, neutral surrogates for cationic factor VIIa P1 group

Protonation switching to the least-basic heteroatom of carbamate through cationic hydrogen bonding promotes the formation of isocyanate cations

We found that phenethylcarbamates that bear ortho-salicylate as an ether group (carbamoyl salicylates) dramatically accelerate O-C bond dissociation in strong acid to facilitate generation of isocyanate cation (N-protonated isocyanates), which undergo subsequent intramolecular aromatic electrophilic cyclization to give dihydroisoquinolones. To generate isocyanate cations from carbamates in acidic media as electrophiles for aromatic substitution, protonation at the ether oxygen, the least basic heteroatom, is essential to promote C-O bond cleavage. However, the carbonyl oxygen of carbamates, the most basic site, is protonated exclusively in strong acids. We found that the protonation site can be shifted to an alternative basic atom by linking methyl salicylate to the ether oxygen of carbamate. The methyl ester oxygen ortho to the phenolic (ether) oxygen of salicylate is as basic as the carbamate carbonyl oxygen, and we found that monoprotonation at the methyl ester oxygen in strong acid resulted in the formation of an intramolecular cationic hydrogen bond (>C=O+-H...O) with the phenolic ether oxygen. This facilitates O-C bond dissociation of phenethylcarbamates, thereby promoting isocyanate cation formation. In contrast, superacid-mediated diprotonation at the methyl ester oxygen of the salicylate and the carbonyl oxygen of the carbamate afforded a rather stable dication, which did not readily undergo C-O bond dissociation. This is an unprecedented and unknown case in which the monocation has greater reactivity than the dication.

17a-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.